Drug
Anifrolumab
Anifrolumab: highest development phase Phase 3, developed by AstraZeneca. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| Anifrolumab NCT07430306 | Phase 3 | Systemic Lupus Erythematosus |
| Anifrolumab NCT07691970 | Phase 3 | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus |
Latest
No recent events.
Follow Anifrolumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.